| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER, Director | C/O TELADOC HEALTH, INC.,, 155 E 44TH ST, FLOOR 17, NEW YORK | /s/ Adam C. Vandervoort, Attorney-in-Fact | 11 Jun 2025 | 0001347535 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TDOC | Common Stock | Options Exercise | +156,641 | 156,641 | 10 Jun 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TDOC | Restricted Stock Units | Options Exercise | $0 | -156,641 | -33% | $0.000000 | 313,283 | 10 Jun 2025 | Common Stock | 156,641 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. |
| F2 | On June 10, 2024, the reporting person was granted 469,924 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |